Single group study to evaluate the feasibility and complications of radiofrequency ablation and usefulness of post treatment position emission tomography in lung tumours

World Journal of Surgical Oncology

Volumn 2, Issue , 2004, Pages

  Kang, Shijun ^a   Luo, Rongcheng ^a   Liao, Wangjun ^a   Wu, Hubing ^a   Zhang, Xuelin ^a   Meng, Yuru ^a  

^a FIRST MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; FLUORODEOXYGLUCOSE;

ADULT; AGED; ARTICLE; CANCER SIZE; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; ELECTRODE; FEASIBILITY STUDY; FEMALE; FEVER; HEMATOTHORAX; HUMAN; LUNG CANCER; MALE; METASTASIS; PNEUMONIA; PNEUMOTHORAX; POSITRON EMISSION TOMOGRAPHY; RADIOFREQUENCY ABLATION; SAFETY; SURGICAL TECHNIQUE; THORAX RADIOGRAPHY;

EID: 12544249516     PISSN: 14777819     EISSN: None     Source Type: Journal    
DOI: 10.1186/1477-7819-2-30     Document Type: Article

References (24)

1. Williams MD, Sandler AB: The epidemiology of lung cancer. Cancer Treat Res 2001, 105: 31-52.
2. Noppen N: Interventional palliative treatment options for lung cancer. Ann Oncol 2002, 13 Suppl 4:247-250.
3. Dupuy DE, Mayo-Smith WW, Abbott GF, DiPetrillo T: Clinical applications of radio-frequency tumor ablation in the thorax. Radiographics 2002, 22 Spec No:S259-69.
4. Chhajed PN, Tamm M: Radiofrequency heat ablation for lung tumors: potential applications. Med Sci Monit 2003, 9: D5-7.
5. Gazelle GS, Goldberg SN, Solbiati L, Livraghi T: Tumor ablation with radio-frequency energy. Radiology 2000, 217: 33-646.
6. Wong CY, Salem R, Raman S, Gates VL, Dworkin HJ: Evaluating 90Y-glass microsphere treatment response of unresectable colorectal liver metastases by [18F]FDG PET: a comparison with CT or MRI. Eur J Nucl Med Mol Imaging 2002, 29:815-820.
7. Wang W, Larson SM, Fazzari M, Tickoo SK, Kolbert K, Sgouros G, Yeung H, Macapinlac H, Rosai J, Robbins RJ: Prognostic value of [18F]fluorodeoxyglucose positron emission tomographic scanning in patients with thyroid cancer. J Clin Endocrinol Metab 2000, 85:1107-1113.
8. Price DT, Coleman RE, Liao RP, Robertson CN, Polascik TJ, DeGrado TR: Comparison of [18 F]fluorocholine and [18 F]fluorodeoxyglucose for positron emission tomography of androgen dependent and androgen independent prostate cancer. J Urol 2002, 168:273-280.
9. Voth M, Opfermann T, Gottschild D: [The value of fluorodeoxyglucose positron emission tomography (FDG-PET) in differentiation of pancreatic lesions]. Zentralbl Chir 2003, 128:375-378.
10. Lowe VJ, Dunphy FR, Varvares M, Kim H, Wittry M, Dunphy CH, Dunleavy T, McDonough E, Minster J, Fletcher JW, Boyd JH: Evaluation of chemotherapy response in patients with advanced head and neck cancer using [F-18]fluorodeoxyglucose positron emission tomography. Head Neck 1997, 19:666-674.
11. Peschina W: [F-18 fluorodeoxyglucose positron emission tomography in lung lesions]. Wien Med Wochenschr 2002, 152: 65-268.
12. Berlangieri SU, Scott AM, Knight SR, Fitt GJ, Hennessy OF, Tochon-Danguy HJ, Clarke CP, McKay WJ: F-18 fluorodeoxyglucose positron emission tomography in the non-invasive staging of non-small cell lung cancer. Eur J Cardiothorac Surg 1999, 16 Suppl 1: 25-30.
13. Hunter GJ, Hamberg LM, Choi N, Jain RK, McCloud T, Fischman AJ: Dynamic T1-weighted magnetic resonance imaging and positron emission tomography in patients with lung cancer: correlating vascular physiology with glucose metabolism. Clin Cancer Res 1998, 4: 49-955.
14. Coleman RE: PET in lung cancer staging. Q J Nucl Med 2001, 45:231-234.
15. Coleman RE: Value of FDG-PET scanning in management of lung cancer. Lancet 2002, 359:1361-1362.
16. Gonzalez-Stawinski GV, Lemaire A, Merchant F, O'Halloran E, Coleman RE, Harpole DH, D'Amico TA: A comparative analysis of positron emission tomography and mediastinoscopy in staging non-small cell lung cancer. J Thorac Cardiovasc Surg 2003, 126:1900-1905.
17. Marom EM, McAdams HP, Erasmus JJ, Goodman PC, Culhane DK, Coleman RE, Herndon JE, Patz E. F., Jr.: Staging non-small cell lung cancer with whole-body PET. Radiology 1999, 212:803-809.
18. Burt BM, Humm JL, Kooby DA, Squire OD, Mastorides S, Larson SM, Fong Y: Using positron emission tomography with [(18)F]FDG to predict tumor behavior in experimental colorectal cancer. Neoplasia 2001, 3:189-195.
19. Coleman RE: FDG imaging. Nucl Med Biol 2000, 27:689-690.
20. Liao WJ, Luo RC, Kang SJ, Wu HB, Wang CB, Luo YL, Zhang MJ: Investigation of short-term therapy results for radiofrequency ablation by positron emission tomography. Di Yi Jun Yi Da Xue Xue Bao 2002, 22:376-377.
21. Kostakoglu L, Goldsmith SJ: 18F-FDG PET evaluation of the response to therapy for lymphoma and for breast, lung, and colorectal carcinoma. J Nucl Med 2003, 44:224-239.
22. Akhurst T, Downey RJ, Ginsberg MS, Gonen M, Bains M, Korst R, Ginsberg RJ, Rusch VW, Larson SM: An initial experience with FDG-PET in the imaging of residual disease after induction therapy for lung cancer. Ann Thorac Surg 2002, 73:259-64; discussion 264-6.
23. Herrera LJ, Fernando HC, Perry Y, Gooding WE, Buenaventura PO, Christie NA, Luketich JD: Radiofrequency ablation of pulmonary malignant tumors in nonsurgical candidates. J Thorac Cardiovasc Surg 2003, 125:929-937.
24. Rose DM, Allegra DP, Bostick PJ, Foshag LJ, Bilchik AJ: Radiofrequency ablation: a novel primary and adjunctive ablative technique for hepatic malignancies. Am Surg 1999, 65: 009-1014.